Expression of the glucocorticoid receptor in renal cell neoplasms: an immunohistochemical and quantitative reverse transcriptase polymerase chain reaction study

Yakirevich, Evgeny; Matoso, Andrés; Sabo, Edmond; Wang, Li J.; Tavares, Rosemarie; Meitner, Patricia A.; Morris, David J.; Pareek, Gyan; DeLellis, Ronald A.; Resnick, Murray B.

doi:10.1016/j.humpath.2011.01.014

Cited by 14 publications

(11 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Univariate analysis showed a longer disease free survival in patients with AR positive tumors compared to patients with AR negative tumors (Langner et al 2004). These results reflect similar trends observed with GRs in RCC (Yakirevich et al 2011), however, the diagnostic, prognostic or therapeutic utility of AR analysis in RCC is uncertain and might require further investigations.…”

Section: Expression Of Ar In Kidney Tumorssupporting

confidence: 72%

“…In an additional study GR mRNA was localized by in-situ hybridization predominantly to renal proximal tubules and cortical collecting tubules with lower levels in distal collecting tubules of the rat kidney (Roland et al 1995). In a recent study we provided immunohistochemical evidence of GR expression in the proximal tubular epithelium of normal human kidneys and in the epithelial cells of normal renal glomeruli (Yakirevich et al 2011 Thomas et al 2006). …”

Section: Expression Of Gr In the Normal Kidneymentioning

confidence: 95%

“…A498 and RCC270 expressed especially high levels of the GR gene (Iwai et al 2004). Recently, using tissue microarray technology and real-time RT-PCR we described the immunohistochemical and mRNA expression of GRs in different histologic subtypes of RCNs including clear cell RCC, papillary RCC, chromophobe RCC, and oncocytoma (Yakirevich et al 2011). We found that GRs are strongly expressed in the majority of clear cell RCCs (66%), in 26% of papillary RCCs, and in only 6% of chromophobe RCC and 14% of oncocytomas.…”

Section: Expression Of Gr In Kidney Tumorsmentioning

confidence: 99%

See 2 more Smart Citations

Steroid Receptors in Renal Cell Carcinoma

Yakirevich¹,

Matoso²,

Morris³

et al. 2012

Emerging Research and Treatments in Renal Cell Carcinoma

Self Cite

View full text Add to dashboard Cite

Section: Expression Of Ar In Kidney Tumorssupporting

confidence: 72%

Section: Expression Of Gr In the Normal Kidneymentioning

confidence: 95%

Section: Expression Of Gr In Kidney Tumorsmentioning

confidence: 99%

See 1 more Smart Citation

Steroid Receptors in Renal Cell Carcinoma

Yakirevich¹,

Matoso²,

Morris³

et al. 2012

Emerging Research and Treatments in Renal Cell Carcinoma

Self Cite

View full text Add to dashboard Cite

“…13 Nonetheless, the status of GR expression in bladder cancer specimens has not been assessed, except in our pilot study of 24 cases of high-grade urothelial carcinoma 13 ; however, it has been reported in other types of malignancy, including non–small cell lung carcinoma 20 and renal cell carcinoma. 21 …”

Section: Discussionmentioning

confidence: 99%

Reduced Glucocorticoid Receptor Expression Predicts Bladder Tumor Recurrence and Progression

Ishiguro

Kawahara

Zheng

et al. 2014

American Journal of Clinical Pathology

View full text Add to dashboard Cite

Objectives To assess the levels of glucocorticoid receptor (GR) expression in bladder tumors because the status and its prognostic value remain largely unknown. Methods We immunohistochemically stained for GR in bladder tumor and matched non-neoplastic bladder tissue specimens. Results Overall, GR was positive in 129 (87%) of 149 urothelial tumors, which was significantly (P = .026) lower than in non-neoplastic urothelium (90 [96%] of 94). Forty-two (79%) of 53 low-grade tumors vs 45 (47%) of 96 high-grade carcinomas (P < .001) and 61 (73%) of 84 non–muscle-invasive (NMI) tumors vs 26 (40%) of 65 muscle-invasive (MI) carcinomas (P < .001) were moderately to strongly immunoreactive for GR. Kaplan-Meier and log-rank tests revealed that loss or weak positivity of GR significantly or marginally correlated with recurrence of NMI tumors (P = .025), progression of MI tumors (P = .082), and cancer-specific survival of MI tumors (P = .067). Multivariate analysis identified low GR expression as a strong predictor for recurrence of NMI tumors (P = .034). Conclusions GR expression was downregulated in bladder tumors compared with nonneoplastic bladder tumors and in high-grade/MI tumors compared with low-grade/NMI tumors. Decreased expression of GR, as an independent prognosticator, predicted recurrence of NMI tumors. These results support experimental evidence suggesting an inhibitory role of GR signals in bladder cancer outgrowth.

show abstract

“…A significant correlation between GR expression and OS in RCC patients may be hypothesized. The majority of patients with ccRCC-expressing GRs were still alive by the end of the follow-up, in contrast to those with expression-negative tumors (59,61). As a result, the correlation of GR expression with less aggressive tumor behavior was reported and the anti-proliferative role of GR signaling in RCC was suggested.…”

Section: Glucocorticoid Receptors (Gr)mentioning

confidence: 99%

Hormone signaling pathways as treatment targets in renal cell cancer (Review)

Czarnecka

Niedzwiedzka

Porta

et al. 2016

International Journal of Oncology

View full text Add to dashboard Cite

Abstract. Epidemiological, clinical, biochemical and genetic research has revealed that renal cell cancer (RCC) etiology is hormone-related. It was shown that hormone receptors are abnormally expressed in RCC cells. Abnormal endocrine stimulation also plays a significant role in RCC pathophysiology. Cellular proliferation, migration, angiogenesis, and drug resistance in RCC is modulated by para-and autocrine hormonal stimulation. In particular, RCC overexpression of gonadotropin-releasing hormone and its receptor was reported. On the contrary, corticotropin releasing hormone was reported to inhibit RCC cell proliferation and regulate angiogenesis. Overexpression of luteinizing hormone also promotes RCC tumor angiogenesis. Estrogen receptor α overexpression increases the transcriptional factor activity of hypoxia inducible factor HIF-1α, but estrogen receptor β has a cancer suppressive role. Glucocorticoid receptors and androgen receptor are markers of indolent RCC and assigned tumor suppressive activity. Proopiomelanocortin is upregulated in VHL-mutated renal cell carcinoma via Nur77 transcription factor signaling. In RCC, follicle-stimulating hormone receptor promotes angiogenesis and metastatic formation via VEGF release. Mineralocorticoid receptor overexpression promotes cell survival and increases RCC cell proliferation. Vitamin D receptor expression is downregulated or absent in RCC and differentiate subtypes of renal cell tumors. RAR-β promotes tumorigenesis but retinoic acid receptor γ expression correlates negatively with the TNM stage at diagnosis. Finally, progesterone receptor expression is negatively correlated with the cancer stage. Molecular data analysis revealed the possibility of renal cancer cell proliferation induction via hormone activated pathways. Inhibition of hormonal signaling may thus play a putative role in supportive therapies against this cancer type.

show abstract

Expression of the glucocorticoid receptor in renal cell neoplasms: an immunohistochemical and quantitative reverse transcriptase polymerase chain reaction study

Cited by 14 publications

References 35 publications

Steroid Receptors in Renal Cell Carcinoma

Steroid Receptors in Renal Cell Carcinoma

Reduced Glucocorticoid Receptor Expression Predicts Bladder Tumor Recurrence and Progression

Hormone signaling pathways as treatment targets in renal cell cancer (Review)

Contact Info

Product

Resources

About